Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistance.
Alkhatib H, Rubinstein AM, Vasudevan S, Flashner-Abramson E, Stefansky S, Chowdhury SR, Oguche S, Peretz-Yablonsky T, Granit A, Granot Z, Ben-Porath I, Sheva K, Feldman J, Cohen NE, Meirovitz A, Kravchenko-Balasha N. Alkhatib H, et al. Among authors: peretz yablonsky t. Genome Med. 2022 Oct 20;14(1):120. doi: 10.1186/s13073-022-01121-y. Genome Med. 2022. PMID: 36266692 Free PMC article.
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer.
Alkhatib H, Conage-Pough J, Roy Chowdhury S, Shian D, Zaid D, Rubinstein AM, Sonnenblick A, Peretz-Yablonsky T, Granit A, Carmon E, Kohale IN, Boughey JC, Goetz MP, Wang L, White FM, Kravchenko-Balasha N. Alkhatib H, et al. Among authors: peretz yablonsky t. Mol Cancer. 2024 Jan 16;23(1):17. doi: 10.1186/s12943-023-01921-9. Mol Cancer. 2024. PMID: 38229082 Free PMC article.